141 related articles for article (PubMed ID: 1156055)
21. [Renal blood flow in hepatic cirrhosis determined by the Xe 133 washout method].
Zuin R; Gatta A; Prandoni P; Finocchio GF; Merkel C; Ruol A
Minerva Nefrol; 1976; 23(2):109-15. PubMed ID: 794762
[No Abstract] [Full Text] [Related]
22. [Changes in renal function in patients with severe hepatitis and liver cancer with cirrhosis during orthotopic liver transplantation].
Li XY; Hei ZQ; Li SR; Shen N
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Jul; 19(7):386-9. PubMed ID: 17631701
[TBL] [Abstract][Full Text] [Related]
23. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
[TBL] [Abstract][Full Text] [Related]
24. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
25. Systemic, splanchnic and renal hemodynamic effects of a dopaminergic dose of dopamine in patients with cirrhosis.
Bacq Y; Gaudin C; Hadengue A; Roulot D; Braillon A; Moreau R; Lebrec D
Hepatology; 1991 Sep; 14(3):483-7. PubMed ID: 1874493
[TBL] [Abstract][Full Text] [Related]
26. Dopamine-induced changes in renal blood flow in normals and in patients with renal dysfunction.
Drieghe B; Manoharan G; Heyndrickx GR; Madaric J; Bartunek J; Sarno G; Vanderheyden M; De Bruyne B
Catheter Cardiovasc Interv; 2008 Nov; 72(5):725-30. PubMed ID: 18949800
[TBL] [Abstract][Full Text] [Related]
27. Distal renal tubular acidosis in hepatic cirrhosis: clinical and pathogenetic study.
Caregaro L; Lauro S; Ricci G; Merkel C; Milani L; Gatta A
Clin Nephrol; 1981 Mar; 15(3):143-7. PubMed ID: 7273489
[TBL] [Abstract][Full Text] [Related]
28. The effect of dopamine on renal cortical blood flow in baboons with experimentally induced obstructive jaundice.
Bomzon L; Wilton PB; Kew MC
Isr J Med Sci; 1978 Oct; 14(10):1069-72. PubMed ID: 104935
[TBL] [Abstract][Full Text] [Related]
29. [The dobutamine-dopamine combination versus amrinone in congestive heart failure with a marked edematogenic sign complicated by functional kidney failure. A comparison between 2 different models of inotropic stimulation and diuresis potentiation].
De Vecchis R; Pucciarelli G; Nocerino L; Cocozza M; Setaro A; Torre G; Imperatore F
Minerva Cardioangiol; 1998 May; 46(5):163-74. PubMed ID: 9842199
[TBL] [Abstract][Full Text] [Related]
30. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine.
Wang DJ; Dowling TC; Meadows D; Ayala T; Marshall J; Minshall S; Greenberg N; Thattassery E; Fisher ML; Rao K; Gottlieb SS
Circulation; 2004 Sep; 110(12):1620-5. PubMed ID: 15337695
[TBL] [Abstract][Full Text] [Related]
31. Nitric oxide synthase inhibition does not improve renal function in cirrhotic patients with ascites.
Thiesson HC; Skøtt O; Jespersen B; Schaffalitzky de Muckadell OB
Am J Gastroenterol; 2003 Jan; 98(1):180-6. PubMed ID: 12526955
[TBL] [Abstract][Full Text] [Related]
32. The role of duplex-doppler ultrasonography in the diagnosis of renal dysfunction and hepatorenal syndrome in patients with liver cirrhosis.
Kastelan S; Ljubicic N; Kastelan Z; Ostojic R; Uravic M
Hepatogastroenterology; 2004; 51(59):1408-12. PubMed ID: 15362765
[TBL] [Abstract][Full Text] [Related]
33. [Hepatorenal syndrome].
Radziszewski A; Sułowicz W
Przegl Lek; 2006; 63(7):573-8. PubMed ID: 17203812
[TBL] [Abstract][Full Text] [Related]
34. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors.
Zipser RD; Radvan GH; Kronborg IJ; Duke R; Little TE
Gastroenterology; 1983 Apr; 84(4):697-703. PubMed ID: 6572162
[TBL] [Abstract][Full Text] [Related]
35. [Hepatorenal syndrome].
Mijac D; Kezić A; Stojimirović B
Srp Arh Celok Lek; 2007; 135(1-2):98-104. PubMed ID: 17503577
[TBL] [Abstract][Full Text] [Related]
36. An experimental hepatorenal syndrome.
Gliedman ML; Carroll HJ; Popowitz L; Mullane JF
Surg Gynecol Obstet; 1970 Jul; 131(1):34-40. PubMed ID: 5419961
[No Abstract] [Full Text] [Related]
37. Renal functional reserve and nitric oxide in patients with compensated liver cirrhosis.
Woitas RP; Heller J; Stoffel-Wagner B; Spengler U; Sauerbruch T
Hepatology; 1997 Oct; 26(4):858-64. PubMed ID: 9328305
[TBL] [Abstract][Full Text] [Related]
38. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine.
Gülberg V; Bilzer M; Gerbes AL
Hepatology; 1999 Oct; 30(4):870-5. PubMed ID: 10498636
[TBL] [Abstract][Full Text] [Related]
39. [Successful conservative therapy of hepatorenal syndrome with vasopressin-1-receptor antagonist ornipressin].
Gülberg V; Luppa P; Pauletzki J; Paumgartner G; Gerbes AL
Z Gastroenterol; 1998 Dec; 36(12):1053-8. PubMed ID: 10025057
[TBL] [Abstract][Full Text] [Related]
40. The hepatorenal syndrome.
Metz RJ; Tompkins RK
Surg Gynecol Obstet; 1976 Aug; 143(2):297-304. PubMed ID: 781880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
